Gleason IP

< Back to News

Gleason IP Testimony Supports Client’s Successful Case

August 3, 2020

Gleason IP provided expert testimony on behalf of Teva Pharmaceuticals to establish that the asserted patent claims allegedly covering Adapt Pharma’s opioid overdose drug were invalid due to obviousness, and that the marketplace performance of Narcan® was attributable to features already known in the prior art, among other extrinsic factors unrelated to the Patents-in-Suit. Engagement In...   Read More

Tags:  Featured , Gleason IP

Remote Depositions in Response to COVID-19

August 3, 2020

The COVID-19 pandemic and related stay-at-home directives have led to an increase in remote depositions.  Historically, attorneys have been reluctant to conduct remote depositions, but there can be certain advantages to be gained from their adoption.  On several occasions, Gleason Managing Directors have been deposed virtually and are providing insight for consideration to aid in...   Read More

Tags:  Featured , Gleason IP

Pricing in the Pharmaceutical Industry

August 3, 2020

Drug pricing in the United States has been a political hot topic in recent years.  On July 24, 2020, President Trump signed four executive orders on lowering drug prices.  This multifaceted issue has numerous stakeholders with far reaching financial impacts. The backdrop of the current global pandemic creates additional complications for pharmaceutical companies seeking to...   Read More

Tags:  Featured , Gleason IP

Patent-Thickets in the News

August 3, 2020

Recently the practice of establishing so called patent-thickets for biologic products has been questioned as a potentially abusive way of preventing biosimilar competition.  In June 2020, the Honorable Judge Manish S. Shah in the United States District Court for the Northern District of Illinois Eastern Division issued a Memorandum Opinion and Order dismissing a class...   Read More

Tags:  Featured , Gleason IP

Spring Continuing Legal Education Series

April 11, 2019

Fairmont Hotel  |  501 Market Street, Pittsburgh, PA 15222 April 10, 12:00-1:00 pm   |   May 7, 7:30-8:30 am   |   June 5, 7:30-8:30 am Gleason is pleased to present a series of continuing legal education sessions at the Fairmont Hotel in downtown Pittsburgh.  Each of these sessions will cover different topics, which are detailed below.  Please feel...   Read More

Tags:  Gleason Experts , Gleason IP , Gleason Trust

Navigating Patent Litigation Changes: Update on the America Invents Act

January 1, 2017

In Issue 3 of IP Insights, we discussed the Inter Partes Review (IPR) process at the United States Patent and Trademark Office (USPTO) since the Leahy-Smith America Invents Act (AIA) was signed into law. The AIA was approved as part of an effort to improve the quality of the patents issued by the USPTO, to...   Read More

Tags:  Gleason IP

Increased Attention on Pharmaceutical Prices

January 1, 2017

As healthcare costs continue to rise, more and more people have entered the debate over escalating drug prices. One situation that has captured the attention of many involves the drug Daraprim®. Daraprim® (pyrimethamine) is used to treat toxoplasmosis in patients with weak immune systems, such as HIV patients.1 Although Daraprim® has been around for over...   Read More

Tags:  Gleason IP

Gleason IP Helps Clients Win Patent Infringement Case

January 1, 2017

Engagement In a pharmaceutical patent infringement matter, Ivan Hofmann and the team at Gleason IP analyzed various issues and provided expert opinions and testimony concerning objective indicia of nonobviousness related to a patent that allegedly covered a lyophilized formulation of the injectable cancer drug bortezomib (marketed as Velcade®). Specifically, Gleason IP analyzed commercial success as...   Read More

Tags:  Gleason IP